Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations

Blood. 2020 Dec 17;136(25):2958-2963. doi: 10.1182/blood.2020006575.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / enzymology
  • Leukemia, Myeloid, Acute* / genetics
  • Male
  • Models, Biological*
  • Mutation*
  • Protein Kinase Inhibitors / administration & dosage
  • Proto-Oncogene Proteins* / antagonists & inhibitors
  • Proto-Oncogene Proteins* / genetics
  • fms-Like Tyrosine Kinase 3* / antagonists & inhibitors
  • fms-Like Tyrosine Kinase 3* / genetics

Substances

  • MEN1 protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3